Equities

Biofrontera Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BFRI:NAQ

Biofrontera Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8948
  • Today's Change-0.029 / -3.17%
  • Shares traded84.92k
  • 1 Year change+2.85%
  • Beta0.6228
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

  • Revenue in USD (TTM)37.17m
  • Net income in USD-17.57m
  • Incorporated2015
  • Employees92.00
  • Location
    Biofrontera Inc120 Presidential Way,, Suite 330WOBURN 01801United StatesUSA
  • Phone+1 (781) 245-1325
  • Fax+1 (302) 655-5049
  • Websitehttps://www.biofrontera-us.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunshine Biopharma Inc37.32m-5.99m5.69m52.00--0.2185--0.1525-2.03-2.0310.745.311.212.0910.12717,764.30-19.47-68.65-23.80-89.0233.0132.79-16.06-81.122.09-209.950.00--44.75340.11-13.94--370.33--
Cuprina Holdings (Cayman) Ltd23.82k-2.22m7.48m14.00--1.24--313.87-0.1223-0.12230.00130.2810.004913.390.79761,701.70-44.56---131.50---69.27---9,194.46--3.58-306.250.0244---52.05---39.39------
Nutraproducts Inc0.00-821.94k7.85m0.00--1.31-----1.31-1.310.000.29730.00-------513.70-1,177.23-740.45-------------385.170.00--------------
Tian'an Pharmaceutical Co Ltd10.65m3.14m8.00m--0.04450.00972.200.75110.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Gelteq Ltd117.46k-4.71m8.29m7.00--0.7399--70.59-0.4993-0.49930.01251.050.0078--0.515516,780.32-31.47-17.38-40.60-19.16-----4,011.74-4,507.46---3.520.2106-------87.40------
cbdMD Inc19.09m-3.71m8.52m42.00--0.9079--0.4463-2.23-2.233.110.89451.642.9515.97---20.06-48.27-41.11-54.9960.5963.95-12.25-85.601.87--0.00---1.50-14.4543.21---32.56--
Nexgel Inc11.67m-2.88m9.20m19.00--1.77--0.7888-0.3796-0.37961.530.63691.053.7913.46613,947.40-25.14-39.08-36.83-49.7938.3019.60-23.91-105.401.08-51.360.1439--112.4764.69-3.93------
Integrated Biopharma Inc52.09m-206.00k9.32m153.00--0.471781.790.179-0.007-0.0071.670.63652.124.9413.32340,464.10-0.83739.98-1.0313.687.8110.74-0.39554.582.67--0.0069--8.020.5933482.30-30.67-0.8556--
Bon Natural Life Ltd18.67m-1.99m10.12m96.0018.630.2316--0.54180.0880.0886.747.080.25416.071.64194,486.40-2.795.82-3.977.8620.7728.53-10.9810.831.61-4.440.17350.00-21.700.4899-577.58--18.20--
Lotus Pharmaceuticals Inc70.79m1.72m10.74m233.000.07340.00112.780.15180.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Biofrontera Inc37.17m-17.57m10.76m92.00------0.2896-1.84-1.844.07-0.22162.192.449.45403,967.40-103.57-48.03-339.69-77.5564.4148.93-47.28-60.990.8033-47.482.37--9.547.3511.78---35.51--
Akari Therapeutics PLC (ADR)0.00-15.77m10.79m8.00---------0.600-0.6000.00--0.00----0.00-65.57-112.46-136.47-257.78-----------27.770.0854-------97.75------
Cellectar Biosciences Inc0.00-18.85m12.68m11.00--1.28-----10.78-10.780.002.940.00----0.00-72.62-104.57-141.24-133.43------------0.00-------4.23--33.54--
CV Sciences Inc14.37m-1.48m14.74m47.00--9.58--1.03-0.008-0.0080.0780.00841.871.6734.74305,659.60-19.21-44.92-66.32-105.3247.0442.89-10.29-49.080.2125-2.020.3829---1.87-21.80-177.18---56.43--
Hoth Therapeutics Inc0.00-12.16m15.82m2.00--1.87-----1.06-1.060.000.54420.00----0.00-138.61-129.47-154.67-144.30-----------493.480.00-------4.37------
Data as of Mar 03 2026. Currency figures normalised to Biofrontera Inc's reporting currency: US Dollar USD

Institutional shareholders

20.75%Per cent of shares held by top holders
HolderShares% Held
Rosalind Advisors, Inc.as of 31 Dec 20251.14m9.79%
AIGH Capital Management LLCas of 31 Dec 2025915.21k7.86%
Matejka & Partner Asset Management GmbHas of 31 Oct 2025104.26k0.90%
Geode Capital Management LLCas of 31 Dec 202565.68k0.56%
Vanguard Fiduciary Trust Co.as of 31 Dec 202561.70k0.53%
The Vanguard Group, Inc.as of 31 Dec 202552.25k0.45%
Jane Street Capital LLCas of 31 Dec 202532.82k0.28%
XTX Markets LLCas of 31 Dec 202518.87k0.16%
Two Sigma Securities LLCas of 31 Dec 202513.48k0.12%
G1 Execution Services LLCas of 31 Dec 202511.55k0.10%
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.